Impact of hospital volume on clinical outcomes of hospitalized heart failure patients: analysis of a nationwide database including 447,818 patients with heart failure

Hidehiro Kaneko1,2*, Hidetaka Itoh1, Haruki Yotsumoto1, Hiroyuki Kiriyama1, Tatsuya Kamon1, Katsuhiro Fujiu1,2, Kojiro Morita3,4, Nobuaki Michihata5, Taisuke Jo6, Norifumi Takeda1, Hiroyuki Morita1, Hideo Yasunaga3 and Issei Komuro1

Abstract

Background: Hospital volume is known to be associated with outcomes of patients requiring complicated medical care. However, the relationship between hospital volume and prognosis of hospitalized patients with heart failure (HF) remains not fully understood. We aimed to clarify the impact of hospital volume on clinical outcomes of hospitalized HF patients using a nationwide inpatient database.

Methods and results: We studied 447,818 hospitalized HF patients who were admitted from January 2010 and discharged until March 2018 included in the Japanese Diagnosis Procedure Combination database. According to the number of patients, patients were categorized into three groups; those treated in low-, medium-, and high-volume centers. The median age was 81 years and 238,192 patients (53%) were men. Patients who had New York Heart Association class IV symptom and requiring inotropic agent within two days were more common in high volume centers than in low volume centers. Respiratory support, hemodialysis, and intra-aortic balloon pumping were more frequently performed in high volume centers. As a result, length of hospital stay was shorter, and in-hospital mortality was lower in high volume centers. Lower in-hospital mortality was associated with higher hospital volume. Multivariable logistic regression analysis fitted with generalized estimating equation indicated that medium-volume group (Odds ratio 0.91, \( p = 0.035 \)) and high-volume group (Odds ratio 0.86, \( p = 0.004 \)) had lower in-hospital mortality compared to the low-volume group. Subgroup analysis showed that this association between hospital volume and in-hospital mortality among overall population was seen in all subgroups according to age, presence of chronic renal failure, and New York Heart Association class.

Conclusion: Hospital volume was independently associated with ameliorated clinical outcomes of hospitalized patients with HF.

Keywords: Hospital volume, Heart failure, Epidemiology

Background

Heart failure (HF) is a major cause of unexpected hospitalization in developed countries, and hospitalization due to HF is also a great economic burden [1–5]. Therefore, providing appropriate acute healthcare services for hospitalized HF patients and building up an optimal medical
care system is strongly required. From the perspective of medical care system, hospital volume attracts clinical interest. Previous studies showed that hospital volume was associated with outcomes of not only patients with advanced cardiovascular diseases [6–9] but also those requiring intensive hospital care [10–12]. Taking these into consideration, hospital volume may influence the outcomes of hospitalized patients with HF. Several preceding studies examined the relationship between hospital volume and outcomes in patients with HF [13–16]. For example, Kumbhani et al. analyzed the Get With The Guidelines-HF registry including elderly HF patients and showed that hospital volume was marginally associated with outcomes up to 6 months of follow-up [13]. However, most of the research in this field was conducted among patients in North America, and real-world data on the association of hospital volume with outcomes of hospitalized HF patients have been insufficient. In this study, we sought to explore the effect of hospital volume on in-hospital outcomes of patients with HF using a nationwide inpatient database in Japan.

**Methods**

**Study design and data source**

The Diagnosis Procedure Combination (DPC) database is a nationwide inpatient database in Japan that includes administrative claims and clinical data for approximately 8 million hospitalized patients per year from more than 1200 participating hospitals including all 82 academic hospitals. The hospitals participating in the DPC database were distributed across all 47 prefectures in Japan. The DPC database represents approximately 50% of all acute inpatients and covers more than 90% of all tertiary-care emergency hospitals in Japan. Academic hospitals are obliged to participate in this database. The participation in this database of community hospitals is voluntary [17–20]. The database collates main diagnoses, comorbidities present at admission, and complications during hospitalization using the International Classification of Disease and Related Health Problems 10th Revision (ICD-10) codes.

**Definition of hospital volume**

We defined hospital volume as the total number of hospitalized patients with HF during the study period at each hospital. We categorized hospitals into tertile (low-, medium-, and high volume) groups, with approximately equal numbers of patients in each group. We divided study patients into three groups by this category.

**Statistical procedure**

Continuous and categorical data were presented as median (interquartile range) and number (percentages), respectively. We compared continuous data using one-way analysis of variance. We performed chi-square analysis to compare categorical variables. Univariate logistic regression analysis was used to identify the association between each covariate (including hospital volume) and in-hospital mortality. The association of hospital volume with in-hospital mortality was evaluated using a multivariable logistic regression analysis with adjustment for other patient backgrounds, while also adjusting for within-hospital clustering using a generalized estimating equation [21]. We performed subgroup analysis according to age, presence of chronic renal failure, and New York Heart Association class. A probability value of <0.05 was considered to indicate statistically significant difference. We performed statistical analysis using SPSS version 25 and STATA version 16.

**Results**

**Study population**

We studied 466,921 patients aged ≥ 20 years with New York Heart Association (NYHA) class ≥ II, admitted and discharged between January 2010 and March 2018 with the main discharge diagnosis of HF defined by ICD-10 codes I50.0, I50.1, and I50.9. Exclusion criteria were as follows: (1) length of hospital stay ≤ 2 days (n = 15,270) and (2) major procedures under general anesthesia (n = 3833). The final number of enrolled patients analyzed was 447,818.

**Baseline clinical characteristics**

Table 1 presents the distribution of the numbers of the patients. We categorized centers into the following three groups according to the volume of hospitals where patients were admitted: low (number of patients < 598), medium (598–1009 patients), and high (>1009). Median age was 81 years, and there was a statistical difference in the percentage of patients aged ≥ 85 years between three groups (p < 0.001). The proportion of patients having NYHA class IV symptom was 30.2% in low volume center, 32.5% in medium volume centers, and 35.5% in high volume center. There was a statistical significant difference in the proportion of patients having NYHA class IV symptom (p < 0.001). The proportion of intravenous use of inotropic agent, nitrate, and furosemide increased with hospital volume category.

**Procedures during hospitalization**

Table 2 summarized procedures and outcomes during hospitalization. There were statistically significant differences in the proportion of patients requiring respiratory support, hemodialysis, and intra-aortic balloon pumping, medical cost, lengths of hospital stay, and in-hospital mortality (all, p < 0.001). The proportion of patients...
### Table 1 Characteristics of study population

| Hospital volume | Low (n = 149,182) | Medium (n = 149,507) | High (n = 149,129) | p value |
|-----------------|-------------------|----------------------|-------------------|---------|
| Number of hospital | 648               | 190                  | 107               |         |
| Number of patients in each hospital | 400 (276–504) | 810 (692–919) | 1405 (1158–1634) |         |
| Age (years) | 81 (72–87)       | 81 (72–87)           | 80 (71–86)        | < 0.001|
| Age ≥ 85 years | 53,068 (35.6)    | 51,603 (34.5)        | 48,549 (32.6)     | < 0.001|
| Male sex | 78,205 (52.4)          | 79,584 (53.2)        | 80,439 (53.9)     | < 0.001|
| Body mass index (kg/m²) | 22.1 (19.6–25.0) | 22.2 (19.6–25.0) | 22.0 (19.5–24.8) | < 0.001|
| Hypertension | 96,539 (64.7)    | 102,989 (68.9)       | 101,547 (68.1)    | < 0.001|
| Diabetes mellitus | 45,518 (30.5)   | 48,361 (32.3)        | 47,140 (31.6)     | < 0.001|
| Chronic renal failure | 20,996 (14.1)   | 22,222 (14.9)        | 22,285 (14.9)     | < 0.001|
| Chronic liver disease | 6086 (4.1)    | 6185 (4.1)           | 5246 (3.5)        | < 0.001|
| Chronic respiratory disease | 17,282 (11.6) | 17,707 (11.8)       | 15,752 (10.6)     | < 0.001|
| Smoking | 43,317 (29.0)         | 48,219 (32.3)       | 52,262 (35.0)     | < 0.001|
| Myocardial infarction | 3,699 (2.5)   | 4,182 (2.8)          | 4,636 (3.1)       | < 0.001|
| Dilated cardiomyopathy | 10,853 (7.3)  | 11,463 (7.7)         | 11,810 (7.9)      | < 0.001|
| Ventricular tachycardia/ventricular fibrillation | 5,751 (3.9)   | 6,664 (4.5)          | 7,874 (5.3)       | < 0.001|
| Shock | 2,918 (2.0)         | 3,167 (2.1)          | 2,680 (1.8)       | < 0.001|
| Anemia | 21,466 (14.4)    | 24,775 (16.6)        | 25,373 (17.0)     | < 0.001|
| Barthel Index | 65 (15–100) | 65 (15–100)           | 55 (5–100)        | < 0.001|
| New York Heart Association |         |                      |                   | < 0.001|
| Class II | 46,002 (30.8)    | 43,519 (29.1)        | 40,294 (27.0)     | < 0.001|
| Class III | 58,106 (38.9)   | 57,366 (38.4)        | 55,967 (37.5)     | < 0.001|
| Class IV | 45,074 (30.2)    | 48,622 (32.5)        | 52,868 (35.5)     | < 0.001|
| **Medications within two days after admission** | | | | |
| Beta blocker | 44,322 (29.7) | 48,517 (32.5) | 55,547 (37.2) | < 0.001|
| Renin-angiotensin system inhibitor | 50,814 (34.1) | 53,377 (35.7) | 62,167 (41.7) | < 0.001|
| Angiotensin converting enzyme inhibitor | 21,565 (14.5) | 23,160 (15.5) | 26,987 (18.1) | < 0.001|
| Angiotensin II receptor blocker | 30,206 (20.2) | 31,180 (20.9) | 36,480 (24.5) | < 0.001|
| Mineralocorticoid receptor antagonist | 44,609 (29.9) | 47,290 (31.6) | 53,716 (36.0) | < 0.001|
| Intravenous inotropic agent | 24,788 (16.6) | 25,138 (16.8) | 28,310 (19.0) | < 0.001|
| Intravenous nitrate | 26,825 (18.0) | 31,741 (21.2) | 34,999 (23.5) | < 0.001|
| Intravenous furosemide | 97,917 (65.6) | 101,240 (67.7) | 105,515 (70.8) | < 0.001|

Data are expressed as median (interquartile range) or number (percentage)

### Table 2 Procedures and clinical outcomes during hospitalization

| Hospital volume | Low (n = 149,182) | Medium (n = 149,507) | High (n = 149,129) | p value |
|-----------------|-------------------|----------------------|-------------------|---------|
| Respiratory support | 19,689 (13.2) | 23,151 (15.5) | 27,814 (18.7) | < 0.001|
| Hemodialysis | 3594 (2.4)         | 3909 (2.6)           | 3882 (2.6)        | < 0.001|
| Intra-aortic balloon pumping | 916 (0.6) | 1073 (0.7) | 1186 (0.8) | < 0.001|
| Extra-corporeal membrane oxygenation | 132 (0.1) | 160 (0.1) | 158 (0.1) | 0.200|
| Cost (JPY) | 712,555 (474,773–1,144,035) | 743,775 (504,863–1,165,348) | 755,800 (519,243–1,181,185) | < 0.001|
| Cost (USD) | 6556 (4368–10,525) | 6843 (4645–10,721) | 6953 (4777–10,867) | < 0.001|
| Length of hospital stay (days) | 18 (11–29) | 17 (11–28) | 16 (11–25) | < 0.001|
| In-hospital death | 11,068 (7.4) | 10,067 (6.7) | 9687 (6.5) | < 0.001|

Data are expressed as median (interquartile range) or number (percentage)
requiring respiratory support and intra-aortic balloon pumping increased with hospital volume category. Medical cost increased, whereas length of hospital stay was reduced with hospital volume. Finally, in-hospital mortality decreased with hospital volume.

**Impact of hospital volume on in-hospital mortality**

Table 3 showed the result of the logistic regression analyses. Univariate logistic regression analysis showed that medium-volume group (Odds ratio 0.90, \( p < 0.001 \)) and high-volume group (Odds ratio 0.87, \( p < 0.001 \)) had lower in-hospital mortality compared to the low-volume group. The multivariable logistic regression analysis fitted with a generalized estimating equation for in-hospital mortality also showed that medium-volume group (Odds ratio 0.91, \( p = 0.035 \)) and high-volume group (Odds ratio 0.86, \( p = 0.004 \)) had lower in-hospital mortality compared to the low-volume group.

**Subgroup analysis**

Figure 1 presents the results of the subgroup analyses. Inverse association between hospital volume and in-hospital mortality was seen in all the subgroups including

### Table 3 Determinants of in-hospital death

|                                | Univariate logistic regression analysis | Multivariable logistic regression fitted with generalized estimating equation |
|--------------------------------|----------------------------------------|-------------------------------------------------------------------------------|
|                                | Odds ratio | 95% Confidence interval | \( p \) value | Odds ratio | 95% Confidence interval | \( p \) value |
| **Hospital volume**            |            |                           |               |            |                           |               |
| Low                            | Reference  |                           |               | Reference  |                           |               |
| Medium                         | 0.90       | 0.88–0.93                 | < 0.001       | 0.91       | 0.83–0.99                 | 0.035         |
| High                           | 0.87       | 0.84–0.89                 | < 0.001       | 0.86       | 0.78–0.95                 | 0.004         |
| **Age (years)**                | 1.05       | 1.05–1.06                 | < 0.001       | 1.04       | 1.04–1.04                 | < 0.001       |
| **Sex**                        |            |                           |               |            |                           |               |
| Female                         | Reference  |                           |               | Reference  |                           |               |
| Male                           | 0.86       | 0.84–0.88                 | < 0.001       | 1.27       | 1.23–1.32                 | < 0.001       |
| **Body mass index (kg/m²)**    | 0.90       | 0.90–0.90                 | < 0.001       | 0.95       | 0.95–0.96                 | < 0.001       |
| Hypertension                   | 0.43       | 0.42–0.44                 | < 0.001       | 0.53       | 0.50–0.55                 | < 0.001       |
| Diabetes mellitus              | 0.78       | 0.76–0.80                 | < 0.001       | 1.03       | 0.99–1.06                 | 0.120         |
| Chronic renal failure          | 1.71       | 1.66–1.75                 | < 0.001       | 1.57       | 1.51–1.63                 | < 0.001       |
| Chronic liver disease          | 1.33       | 1.26–1.40                 | < 0.001       | 1.45       | 1.36–1.55                 | < 0.001       |
| Chronic respiratory disease    | 1.01       | 0.98–1.05                 | 0.568         | 0.98       | 0.94–1.03                 | 0.473         |
| Myocardial infarction          | 1.93       | 1.83–2.04                 | < 0.001       | 1.46       | 1.35–1.57                 | < 0.001       |
| Dilated cardiomyopathy         | 0.87       | 0.83–0.91                 | < 0.001       | 1.19       | 1.13–1.26                 | < 0.001       |
| Smoking                        | 0.68       | 0.66–0.69                 | < 0.001       | 0.88       | 0.85–0.92                 | < 0.001       |
| **New York Heart Association** |            |                           |               |            |                           |               |
| **Class II**                   |            |                           |               |            |                           |               |
| Class III                      | 1.92       | 1.85–1.99                 | < 0.001       | 1.68       | 1.58–1.79                 | < 0.001       |
| Class IV                       | 4.49       | 4.33–4.66                 | < 0.001       | 3.36       | 3.11–3.63                 | < 0.001       |
| Ventricular tachycardia/ventricular fibrillation | 1.77 | 1.69–1.85 | < 0.001 | 1.97 | 1.83–2.11 | < 0.001 |
| **Shock**                      | 5.76       | 5.49–6.04                 | < 0.001       | 3.20       | 2.85–3.60                 | < 0.001       |
| Anemia                         | 1.55       | 1.50–1.59                 | < 0.001       | 1.35       | 1.30–1.41                 | < 0.001       |
| Barthel Index per 10           | 0.84       | 0.83–0.84                 | < 0.001       | 0.89       | 0.89–0.90                 | < 0.001       |
| **Administration within two days** |       |                           |               |            |                           |               |
| Beta blocker                   | 0.61       | 0.59–0.63                 | < 0.001       | 0.94       | 0.90–0.97                 | < 0.001       |
| Renin-angiotensin system inhibitor | 0.41 | 0.40–0.42 | < 0.001 | 0.62 | 0.60–0.65 | < 0.001 |
| Mineralocorticoid receptor antagonist | 0.63 | 0.61–0.65 | < 0.001 | 0.83 | 0.80–0.86 | < 0.001 |
| Intravenous inotropic agent    | 2.88       | 2.81–2.95                 | < 0.001       | 2.13       | 2.04–2.23                 | < 0.001       |
| Intravenous nitrate            | 0.64       | 0.62–0.66                 | < 0.001       | 0.57       | 0.54–0.60                 | < 0.001       |
| Intravenous furosemide         | 1.32       | 1.29–1.36                 | < 0.001       | 0.97       | 0.94–1.01                 | 0.172         |
age (A), presence of chronic renal failure (B), and NYHA class (C).

**Discussion**

Using a nationwide inpatient database of hospitalized patients with HF, we examined the influence of hospital-volume on clinical outcomes of HF patients. The key findings of the present study are as follows: (1) Patients in higher volume hospitals had more severe condition at admission. (2) Higher volume hospitals provided advanced cardiorespiratory support more aggressively. (3) Patients admitted in high volume hospitals had lower in-hospital mortality compared to those admitted to low volume hospitals even after adjustment for the covariates.

Baseline NYHA class increased with hospital volume, suggesting that patients admitted to higher volume centers were more severe than those admitted to low volume centers. Nevertheless, clinical outcomes were better in high volume centers than in low volume centers in association with early administration of medical agents and aggressive advanced cardiorespiratory supports.

In this study, we performed the multiple logistic regression analysis fitted with generalized estimating equation to identify the determinants of in-hospital death. Results of the multiple logistic regression analysis such as the association of chronic liver disease [22–24] and cigarette smoking (so called “smoker’s paradox” [25, 26]) with outcomes were concordant with preceding studies focusing on patients with HF, and our results demonstrated that hospital volume was independently associated with in-hospital mortality among patients hospitalized for HF.

Our findings were concordant with those in previous studies on the association between hospital volume and outcomes of HF patients, which also indicated that higher center volume was associated with lower mortality [14, 16]. On the contrary, the analysis of the Get With The Guidelines-HF registry which was linked to Medicare inpatient data of 342 hospitals showed that hospital volume was marginally associated with chronic phase outcomes, but not associated with in-hospital mortality [13]. Therefore, there has remained a room for further investigations in this field. Moreover, considering that previous studies examined patients limited to specific health insurance or community, our study has several advantages. Japan has a universal health care insurance system and patients are provided with equal health care access with equal fees which the Japanese government set. Further, our database is a nationwide inpatient database.
database which could exclude region specific factors. Therefore, this study has strength in generalizability. Previous studies [14, 16] showed that higher hospital volume was associated with medical costs, and our study showed a similar trend. However, the difference in medical costs between low and high hospital volume hospitals was not so large in this study. Longer hospital stay in low volume hospitals and advanced procedures in high volume centers seemingly offset the difference in medical costs.

Several possible explanations can be suggested for the relationship between hospital volume and clinical outcomes. First, therapeutic management for hospitalized HF patients is complex and complicated. It requires a multidisciplinary team approach including primary care physicians, cardiologists, HF specialists, intensivists, cardiac surgeons, nurses, pharmacists, nutritionists, and physiotherapists who had not only professional training but also a great deal of experience in real-world clinical practice. Health care professionals in high volume centers may be more familiar with advanced treatment for hospitalized patients with HF. Therefore, rich experience in high volume centers may lead to better clinical outcomes. Second, various complications such as hemodynamic collapse, life-threatening arrhythmia, acute kidney injury, multiorgan dysfunction, stroke, and infection can occur during the clinical course of hospitalized patients with HF, and these complications require quick and appropriate management. A previous study reported that high volume centers could provide better management for complications in patients undergoing cardiac surgeries [27]. Therefore, better outcomes in high volume centers may attribute to better management for complications in patients with HF. Third, high volume centers may have more healthcare professional staffs and medical infrastructure. Abundant medical resources can also contribute to favorable outcomes in high volume centers. Finally, it could be also possible that better prognosis of HF patients leads to an increase in the number of patients through referral and results in further increase in hospital volume.

This study has clinical implications. As the prevalence of HF is increasing, nationwide actions for the optimal management of HF are required [28, 29]. From this point of view, establishing medical system for HF is important. The results of the present study suggest the importance of high volume centers for HF treatment. On the other hand, maintaining appropriate hospital access for patients with HF in each geographic region is essential because patients with acute HF requiring hospital admission need accessible hospitals which can provide emergency medical care. Therefore, low volume centers in each area is also indispensable. However, considering that the difference in in-hospital mortality according to hospital volume was seemingly pronounced in patients with severe conditions such as older age, chronic renal failure, and NYHA class IV, primary risk stratification for HF patients is important and we should prepare regional medical system for patients with HF. For example, it may be useful that emergency service or primary physicians determine a hospital where patients are transferred according to estimated severity of patients with HF.

There are several limitations in this study. We performed the multivariable logistic regression analysis to adjust for covariates, but a possibility of residual bias could not be eliminated. Because of the nature of the retrospective design, recorded diagnoses are commonly less well validated. Hospital volume was defined as the total number of hospitalized patients with HF during the study period at each hospital. Although some hospitals could have periods of time when they were not enrolling patients, we did not have enough information to assess this point in detail. Our database lacked data regarding blood pressure, heart rate (tachycardia and bradycardia), arrhythmia, HF etiology, left ventricular ejection fraction, diastolic function, right ventricular function, biomarkers such as brain natriuretic peptide, and other concomitant diseases, which can affect the clinical outcomes of hospitalized HF patients. In addition to these, other many factors are associated with the outcomes of HF patients. For example, serum uric acid level is also known to affect the prognosis of patients with HF [30, 31]. However, data on serum uric acid level were not available in this study. A previous study reported that higher hospital volume was associated with lower 6-month mortality and lower 6-month readmissions in patients with HF [13]. However, the long-term prognosis could not be assessed in this database.

Conclusion
The analysis of a nationwide inpatient database including 447,818 hospitalized HF patients showed better clinical outcomes of HF patients in high volume centers compared to those in low volume centers. We believe that the results of this study are resourceful for preparing medical care system for hospitalized HF patients in the era of increasing prevalence of HF worldwide.

Abbreviations
DPC: Diagnosis Procedure Combination; HF: Heart failure; ICD-10: International Classification of Disease and Related Health Problems 10th Revision; NYHA: New York Heart Association.

Authors’ contributions
HK1: Corresponding author. Conception and design or analysis and interpretation of data. Drafting of the manuscript; HI: Analysis of data; HY: Analysis of data; HK2: Revising it critically for important intellectual content; TK: Analysis of data; KF: Revising it critically for important intellectual content; KM: Analysis and interpretation of data; NNM: Analysis and interpretation of data; TJ: Data
collection. Analysis and interpretation of data; NT: Revising it critically for important intellectual content; HM: Revising it critically for important intellectual content; HY: Conception and design or analysis and interpretation of data. Final approval of the manuscript submitted; IK: Final approval of the manuscript submitted.

Funding
This work was supported by grants from the Ministry of Health, Labour and Welfare, Japan (19KA2007 and H30-Policy-Designated-004) and the Ministry of Education, Culture, Sports, Science and Technology, Japan (17H04141) for the design of study and data collection. Hidehiko Kaneko and Katsuhiro Fujiu obtained research funding and scholarship funds (Hidehiko Kaneko and Katsuhiro Fujiu) from Medtronic Japan CO, LTD, Biotronik Japan, SIMPLEX QUANTUM CO, LTD, Boston Scientific Japan CO, LTD, and Fukuda Denshii, Central Tokyo CO, LTD. These findings were not relevant to this study.

Availability of data and materials
The datasets analyzed during the current study are not publicly available due to contracts with the hospitals providing data to the database.

Ethics approval
This study was approved by the Institutional Review Board of The University of Tokyo (3501-03). We conducted this study in accordance with the Declaration of Helsinki. Because of the anonymous nature of this database, the requirement for informed consent was waived.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 The Department of Cardiovascular Medicine, The University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. 2 The Department of Advanced Cardiology, The University of Tokyo, Tokyo, Japan. 3 The Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. 4 The Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. 5 The Department of Health Services Research, The University of Tokyo, Tokyo, Japan.

Received: 17 May 2020 Accepted: 11 January 2021
Published online: 25 January 2021

References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Halpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, May CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Vriniotis SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics C, Stroke Statistics S. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-245. https://doi.org/10.1161/CIR.0b013e31821244ad.
2. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA. 2011;306:1669–78. https://doi.org/10.1001/jama.2011.1474.
3. Jenkins SE, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2006;350:1418–28. https://doi.org/10.1056/NEJMsa0603563.
4. Storrow AB, Jenkins CA, Self WH, Alexander PT, Barrett TW, Han JH, McNaughton CD, Heavrin BS, Gheorghiade M, Collins SP. The burden of acute heart failure on U.S. emergency departments: JACC Heart Fail. 2014;2:269–77. https://doi.org/10.1016/j.jchf.2014.01.006.
5. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol. 2008;52:428–34. https://doi.org/10.1016/j.jacc.2008.03.061.
6. Post PN, Kuijpers M, Ebelis T, Zijlstra F. The relation between volume and outcome of coronary interventions: a systematic review and meta-analysis. Eur Heart J. 2010;31:1985–92. https://doi.org/10.1093/eurheartj/ehq15.
7. Russo MJ, Irbarane A, Easterwood R, Ibrahimimbey AN, Davies R, Hong KN, Ascheim DD, Gelijns AC, Naka Y. Post-heart transplant survival is inferior at low-volume centers across all risk strata. Circulation. 2010;122:585–91. https://doi.org/10.1161/CIRCULATIONAHA.109.926659.
8. Inohara T, Kobasaka S, Yamaji K, Amano T, Fuji K, Oda H, Umemura S, Kadota K, Miyata H, Nakamura M. Investigators JPR. Impact of institutional and operator volume on short-term outcomes of percutaneous coronary intervention: a report from the Japanese Nationwide Registry. JACC Cardiovasc Inter. 2017;9:108–27. https://doi.org/10.1016/j.jcin.2017.02.015.
9. Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS, Kumbhani DJ, Ruiz CE, Thouren VH, Hansel G, Gleason TG, Herrmann HC, Bindis RG, Bavaria JE. Procedural volume and outcomes for transcatheter aortic-valve replacement. N Engl J Med. 2019;380:2541–50. https://doi.org/10.1056/NEJMs a1901109.
10. Nathens AB, Jurkovich GJ, Maier RV, Grossman DC, Mackenzie EJ, Moore M, Rivara FP. Relationship between trauma center volume and outcomes. JAMA. 2001;285:1164–71. https://doi.org/10.1001/jama.285.9.1164.
11. Light TD, Latenser BA, Kealey GP, Wibbenmeyer LA, Rosenthal GE, Sarazin MV. The effect of burn center and burn center volume on the mortality of burned adults—an analysis of the data in the National Burn Repository. J Burn Care Res. 2009;30:776–82. https://doi.org/10.1097/BCR.0b013e3181 b47ed2.
12. Worthington H, Pickett W, Morrison LJ, Scales DC, Zhan C, Lin S, Dorian P, Damy KN, Ferguson ND, Brooks SC, Rescu I. The impact of hospital experience with out-of-hospital cardiac arrest patients on post cardiac arrest care. Resuscitation. 2017;110:169–75. https://doi.org/10.1016/j.resuscitation.2016.08.032.
13. Kumbhani DJ, Fonarow GC, Heidenreich PA, Schulte PJ, Lu D, Hernandez A, Yancy C, Bhatt DL. Association between hospital volume, processes of care, and outcomes in patients admitted with heart failure: insights from the get with the guidelines-heart failure. Circulation. 2018;137:1661–70. https://doi.org/10.1161/CIRCULATIONAHA.117.028077.
14. Madan S, Sims D, Saeed O, Patel SR, Shin JJ, Jorde UP. Association of centre volume and in-hospital mortality in heart failure hospitalisations. Postgrad Med J. 2017;93:534–40. https://doi.org/10.1136/postgradmed j-2016-134697.
15. McAlister FA, Youngson E, van Diepen S, Ezekowitz JA, Kaul P. Influence of hospital volume on outcomes for patients with heart failure: evidence from a Canadian national cohort study. Am Heart J. 2018;202:148–50. https://doi.org/10.1016/j.ahj.2018.05.014.
16. Joynt KE, Orav EJ, Jha AK. The association between hospital volume and processes, outcomes, and costs of care for congestive heart failure. Ann Intern Med. 2011;154:94–102. https://doi.org/10.7326/0003-4819-154-2-201101180-00008.
17. Kaneko H, Itoh H, Yotsutomo H, Kiyirama H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Morita H, Yasunaga H, Komuro I. Characteristics and outcomes of superelderly patients (aged ≥90 years) hospitalized for heart failure—analysis of a nationwide inpatient database. Circ J. 2020;2:393–9.
18. Kaneko H, Itoh H, Yotsutomo H, Kiyirama H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Takeda N, Morita H, Yasunaga H, Komuro I. Association of cancer with outcomes in patients hospitalized for heart failure. Circ J. 2020;84:1771–8. https://doi.org/10.1253/circj .CJ-20-0314.
19. Kaneko H, Itoh H, Yotsutomo H, Kiyirama H, Kamon T, Fujiu K, Morita K, Michihata N, Jo T, Morita H, Yasunaga H, Komuro I. Association between the number of hospital admissions and in-hospital outcomes in patients with heart failure. Hypertens Res. 2020. https://doi.org/10.1038/s4144 0-020-0050-2.
20. Itoh H, Kaneko H, Kiyirama H, Kamon T, Fujiu K, Morita K, Yotsutomo H, Michihata N, Jo T, Takeda N, Morita H, Yasunaga H, Komuro I. Reverse J-shaped relationship between body mass index and in-hospital mortality of patients hospitalized for heart failure in Japan. Heart Vessels. 2020. https://doi.org/10.1007/s10038-020-01699-6.
21. Hanley JA, Negassa A, Edewar MF, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157:364–7. https://doi.org/10.1093/aje/kvf215.
22. Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Lanib S, Paugam-Burtz C, Bai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A, Mebazaa A. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013;34:742–9. https://doi.org/10.1093/eurheartj/ehs332.

23. Inohara T, Kohsaka S, Shiraishi Y, Goda A, Sawano M, Yagawa M, Mahara K, Fukuda K, Yoshikawa T, West Tokyo Heart Failure Registry I. Prognostic impact of renal and hepatic dysfunction based on the MELD-XI score in patients with acute heart failure. Int J Cardiol. 2014;176:571–3. https://doi.org/10.1016/j.ijcard.2014.08.052.

24. Xanthopoulos A, Starling RC, Kitai T, Tripodis F. Heart failure and liver disease: cardiohepatic interactions. JACC Heart Fail. 2019;7:87–97. https://doi.org/10.1016/j.jchf.2018.10.007.

25. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Nunez E, Yancy CW, Young JB. A smoker’s paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J. 2008;29:1983–91. https://doi.org/10.1093/eurheartj/ehn210.

26. Doi SA, Islam N, Suleman K, Alsheikh-Ali AA, Singh R, Al-Qahtani A, Aasaa N, Ahabib EF, Al-Zakwani I, Al-Jarallah M, Al-Mahmeed W, Bulbanat B, Bazargani N, Amin H, Al-Motarreb A, Al-Faleh H, Panduranga P, Shehab A, Al Suwaidi J, Salam AM. Demystifying Smoker’s paradox: a propensity score-weighted analysis in patients hospitalized with acute heart failure. J Am Heart Assoc. 2019;8:e013056. https://doi.org/10.1161/JAHA.119.013056.

27. Ghafari AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. N Engl J Med. 2009;361:1368–75. https://doi.org/10.1056/NEJMsa0903048.

28. Komuro I, Kaneko H, Morita H, Isobe M, Nakayama H, Minematsu K, Yamaguchi T, Yazaki Y. Nationwide actions against heart failure pandemic in Japan—what should we do from academia? Circ J. 2019;83:1819–21. https://doi.org/10.1253/circj.CJ-19-0562.

29. Kaneko H, Morita H, Komuro I. Beautiful harmony of the Japanese precious healthcare legacies for the new imperial era. Circ J. 2020;84:371–3. https://doi.org/10.1253/circj.CJ-19-1059.

30. Anker SD, Doehnert W, Rauchhaus M, Sharma R, Francis D, Knoска C, Davos CH, Ciciria M, Shimmin W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991–7. https://doi.org/10.1161/01.CIR.0000065637.10517.A0.

31. Pascual-Figal DA, Hurtado-Martinez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007;9:518–24. https://doi.org/10.1016/j.ejheart.2006.09.001.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.